20250902-招银国际-豪威集团-603501.SH-Solid_1H25_results_Maintain_BUY_5页_1mb

OmniVision Equity Research Summary

Executive Summary

OmniVision (603501 CH) reported strong 1H25 financial results with 15% YoY revenue growth. The company maintains a BUY recommendation with an updated Target Price of RMB173.00.

Performance Analysis

• Revenue: Revenues reached a record RMB10.3bn in CIS (up +11% YoY) driven by solid performance from Analog Solutions (+21% YoY) and Distribution (+42% YoY). Overall revenue rose 15% YoY to RMB14bn.
• Profitability: Net profit surged 48% YoY to RMB2bn while Net Profit Margin (NPM) improved significantly to 14.5%.
• Segment Growth: Strong growth in Auto CIS (+30% YoY), Medical CIS (+68% YoY), and Emerging IoT (+249% YoY). Mobile CIS faced weakness (-19% YoY).
• Outlook: Maintains BUY due to significant growth projections across auto/medical, strong market positioning, and new product cycles despite mobile CIS headwinds.

Market Position & Technology

• Leadership: Strong market share in Auto CIS and Medical CIS (approx. 30% per TechInsights).
• China Policy: Well-positioned for China's "Intelligent Driving Equality" policy supporting Auto CIS growth.
• Technology: Benefits from high-end product adoption (Nyxel, OV50H/EOL impact) and developing positions in 200MP sensors.

Financial Analysis

• Revenue Projections: Forecasts 18% in 2025E and 25% in 2026E revenue growth. EPS perspective is constructive.
• Valuation: Primary growth driver, BUY rating aligned with a 33.6x 2026E P/E. Pricing reflects this valuation.
• Risk Factors: Smart phone shipments (post-Cycle), market share erosion due to competition, and slower recovery than expected were risks previously considered, with a moderate reduction in 2025/26E net profit forecasts.
• Balance Sheet: Appears healthy.

Investor Takeaway

Investor takeaway focuses on the company's strong position in expanding market segments (Auto, Medical, Emerging IoT) and its potential to maintain强劲盈利增长 despite mobile-related cycles.